Kitaguchi Nobuya, Kato Takashi, Matsunaga Shinji, Hirano Kyoko, Iwata Kaori, Kawaguchi Kazunori, Fujita Kiyoshi, Takechi Hajime, Hasegawa Midori, Yuzawa Yukio, Ito Kengo
School of Health Sciences, Fujita Health University, Toyoake, Aichi, Japan,
Department of Brain Science and Molecular Imaging, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Neuropsychiatr Dis Treat. 2018 Nov 1;14:2931-2937. doi: 10.2147/NDT.S186118. eCollection 2018.
The accumulation of amyloid-β protein (Aβ) in the brain signifies a major pathological change of Alzheimer's disease (AD). Extracorporeal blood Aβ removal system (E-BARS) has been under development as a tool for enhancing the clearance of Aβ from the brain. Previously, we revealed that dialyzers remove blood Aβs effectively, evoking substantial Aβ influx into the blood during hemodialysis sessions as one form of blood Aβ removal by E-BARS, and that postmortem brains of hemodialysis patients exhibited lower Aβ accumulation. Here, we present a case report of a 77-year-old male patient with end-stage renal failure whose Aβ accumulation in the brain declined by initiating and continuing hemodialysis for 6 months. This report suggests that blood Aβ removal by E-BARS could be an effective therapeutic method for AD.
大脑中β淀粉样蛋白（Aβ）的积累是阿尔茨海默病（AD）的主要病理变化。体外血液Aβ清除系统（E-BARS）作为一种增强大脑中Aβ清除的工具正在开发中。此前，我们发现透析器能有效清除血液中的Aβ，在血液透析过程中引起大量Aβ流入血液，这是E-BARS清除血液中Aβ的一种形式，并且血液透析患者的死后大脑显示出较低的Aβ积累。在此，我们报告一例77岁终末期肾衰竭男性患者的病例，通过开始并持续进行6个月的血液透析，其大脑中的Aβ积累有所下降。本报告表明，E-BARS清除血液中的Aβ可能是一种有效的AD治疗方法。
